Poland· PL-100081343
Retrovir
A zidovudine product containing zidovudinum, registered in Poland by ViiV Healthcare BV. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Zidovudine is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AF01 (zidovudine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Zidovudine · ATC J05AF01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of zidovudine costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Zidovudine · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$10.96
The record
At a glance
URPL (Poland)- Active substance
- Zidovudinum
- Manufacturer
- ViiV Healthcare BV
- Country
- Poland (PL)
- ATC code
- J05AF01
- ATC class
- Zidovudine
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909990769919
- gtin05099211002182
- gtin05099211005473
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
321 interactions on record for zidovudine.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zidovudine · interactions on record
321 records
- 36 severe
- 220 moderate
- 9 minor
- 55 info
Most severe, free to view
- CladribineL01BB04severe
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- Amphotericin BA07AA07moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Zidovudine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRETROVIRViiV Healthcare BV, Amersfoort
- IrelandRetrovir 10 mg/ml IV concentrate for solution for infusionViiV Healthcare BV
- NorwayRetrovirViiV Healthcare BV
- SwedenRetrovir 10 mg/ml Koncentrat till infusionsvätska, lösningViiV Healthcare BV
- BelgiumCombivir 150 mg - 300 mgViiV Healthcare
- United KingdomRetrovir 100mg capsulesViiV Healthcare UK Ltd
- United StatesRETROVIRViiV Healthcare Company
- GermanyRetrovirViiv Healthcare B.V.
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Retrovir
- Belgium · Retrovir, Retrovir I.V.
- Bulgaria · Ретровир
- Czechia · Retrovir
- Germany · Retrovir, Retrovir I.V.
- Denmark · Retrovir
- Estonia · Retrovir
- Spain · Retrovir, Zidovudina Accord
- Finland · Retrovir
- France · Retrovir
- United Kingdom (Northern Ireland) · Retrovir, Retrovir Iv
- Greece · Retrovir
- Ireland · Retrovir
- Italy · Retrovir
- Luxembourg · Retrovir, Retrovir I.V.
- Netherlands · Retrovir, Retrovir Infuus
- Portugal · Retrovir, Retrovir Iv
- Romania · Retrovir
- Sweden · Retrovir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7ba2ffc8-f18e-4d47-8753-9989b6e8edaa GET /v1/drugs/7ba2ffc8-f18e-4d47-8753-9989b6e8edaa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mg/ml",
"packaging": "05909990769919 ¦ Lz ¦ 12237\n5 fiol. 20 ml\n¦ UR/Z/4c/071/22 - 05099211002182 ¦ UR/Z/4c/046/22 - 05099211002182 ¦ UR/Z/4c/128/24 - 05099211005473 ¦ UR/Z/4c/167/23 - 05099211002182 ¦ UR/Z/4c/276/25 - 05099211002182 ¦ UR/Z/4c/204/25 - 05099211002182",
"substance": "Zidovudinum 10 mg/ml",
"common_name": "Zidovudinum",
"pl_product_id": "100081343",
"pozwolenie_nr": "07699",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about zidovudine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.